Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Stifel analyst Dara Azar initiated coverage on Inhibrx Biosciences Inc (NASDAQ:INBX) with a Buy rating and announced a price target of $150. Inhibrx Biosciences shares closed at $62.35 on Tuesday. See how other analysts view this stock.
• Needham analyst Ami Fadia initiated coverage on MapLight Therapeutics Inc (NASDAQ:MPLT) with a Buy rating and announced a price target of $37. MapLight Therapeutics shares closed at $24.14 on Tuesday. See how other analysts view this stock.
• Stifel analyst Dara Azar initiated coverage on Summit Therapeutics Inc (NASDAQ:SMMT) with a Buy rating and announced a price target of $45. Summit Therapeutics shares closed at $19.22 on Tuesday. See how other analysts view this stock.
• Evercore ISI Group analyst Elizabeth Anderson initiated coverage on Elevance Health Inc (NYSE:ELV) with an In-Line rating and announced a price target of $345. Elevance Health shares closed at $311.83 on Tuesday. See how other analysts view this stock.

Considering buying INBX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.